EDESA BIOTECH INC (EDSA)
CA27966L3065 - Common Stock
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q4 2023
EDSA stock results show that Edesa Biotech beat analyst estimates for earnings per share the fourth quarter of 2023.
EDSA Stock Earnings: Edesa Biotech Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Edesa Biotech (NASDAQ:EDSA) just reported results for the fourth quarter of 202...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!
Edesa Biotech falls after 1-for-7 reverse stock split announcement (NASDAQ:EDSA)
Edesa Biotech stock falls 10% after announcement of 1-for-7 reverse stock split.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Edesa Biotech appoints CFO (NASDAQ:EDSA)
Biopharmaceutical company Edesa Biotech (EDSA) said on Tuesday that its board has appointed Stephen Lemieux CFO, effective July 15.
Edesa stock slumps 30% amid skin rash drug's mixed phase 2b trial results
Edesa Biotech (EDSA) stock fell ~33% on Tuesday after the company reported data from a phase 2b trial of skin disorder therapy EB01The company is exploring EB01 as a monotherapy...
What Is Going on With Edesa Biotech (EDSA) Stock Today?
Edesa Biotech released encouraging Phase 2 results for its respiratory-syndrome-targeting antibody, thus initially boosting EDSA stock.
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2022 and provided an update on its business.
Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference
TORONTO, ON / ACCESSWIRE / August 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being held in New York, NY on August 8-9, 2022. The hybrid event will be held both virtually and in-person.
Edesa Biotech to Present at ARDS Drug Development Summit
TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the 2nd Annual ARDS Drug Development Summit being held July 13-15, 2022 in Boston, Mass.
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has initiated enrollment for a second cohort of patients for the Phase 3 part of a Phase 2/3 study of the company's critical care drug candidate, designated EB05.
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2022 and provided an update on its business. For its critical care drug candidate, Edesa reported during the quarter that more than 25% of the subjects have been randomized for the Phase 3 part of